4 Healthcare Stock Stories Prescribed For Investors

AbbVie (NYSE: ABBV): Closing price $46.26

On Monday, AbbVie announced the beginning of a Phase 3 clinical study named SONAR (Study Of Diabetic Nephropathy with Atrasentan) to evaluate the effects of the investigational compound atrasentan, when added to standard of care, on progression of kidney disease in patients having stage 2 to 4 chronic kidney disease  and type 2 diabetes. SONAR is a large, double-blind, multinational, placebo-controlled clinical study that should enroll in excess of 4,000 patients with diabetic nephropathy. The study will examine atrasentan’s impact on renal outcomes, like the onset of end-stage renal disease, as defined by need for chronic dialysis, transplant or death because of renal failure progression.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ABBV

Acorda Therapeutics (NASDAQ:ACOR): Closing price $32.16

Acorda on Monday, said that the United States Patent and Trademark Office has issued its Patent Application No. 8,440,703 entitled Methods of Using Sustained Release Aminopyridine Compositions. The ’703′ patent includes claims directed to methods of improving lower extremity function and walking, and accelerating walking speed in patients suffering from multiple sclerosis by administering under 15 mg of sustained release 4-aminopyridine (dalfampridine) twice a day. The 703 patent will expire in 2025, and is eligible for listing in the FDA Orange Book.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACOR

Covidien (NYSE:COV): Closing price $65.54

Covidien reports that its Nellcor” pulse oximetry portfolio, which is used to measure arterial oxygen saturation, has won FDA 510k clearance for motion claims. The approval makes Covidien the first firm to receive FDA clearance for a motion-tolerant bedside pulse oximeter portfolio that is compliant with ISO 80601-2-61 (International Organization for Standardization standards for pulse oximetry) as well. Covidien is a world provider of healthcare products and an innovator in patient monitoring and respiratory care devices.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

COV

XenoPort (NASDAQ:XNPT): Closing price $5.72

The firm announced Monday top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil for the treatment of patients suffering from spasticity because of multiple sclerosis. The trial was unsuccessful in showing that AP provided statistically significant improvement versus placebo in the co-primary endpoints of the evaluation.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

XNPT

Investing Insights: Is WebMD a Strong Play Here?

More Articles About:    

More from The Cheat Sheet